Durect corporation to present additional clinical data from dur-928 studies in nash (phase 1b) and in hepatic impairment (phase 1) at upcoming international liver conference 2021 (easl)

Cupertino, calif., june 9, 2021 /prnewswire/ -- durect corporation (nasdaq: drrx) today announced it will present two posters at the 2021 international liver conference (easl) to be held virtually june 23-26, 2021.

DRRX Ratings Summary

DRRX Quant Ranking